Gene Therapy Through Autologous Transplantation of Gene-Modified Hematopoietic Stem Cells

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1 SUPPL., 2013, Pages

  Kohn, Donald B ^a   Pai, Sung Yun ^b   Sadelain, Michel ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HEMOGLOBIN BETA CHAIN; RETROVIRUS VECTOR;

ADENOSINE DEAMINASE DEFICIENCY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BETA THALASSEMIA; CHRONIC GRANULOMATOUS DISEASE; DISEASE FREE SURVIVAL; DNA MODIFICATION; FUNDING; GENETIC DISORDER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMOGLOBINOPATHY; HUMAN; LEUKOCYTE ADHESION DEFICIENCY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; SEVERE COMBINED IMMUNODEFICIENCY; SICKLE CELL ANEMIA; SURVIVAL RATE; VIRAL GENE THERAPY; VIRUS CARCINOGENESIS;

ANIMALS; GENETIC DISEASES, INBORN; GENETIC THERAPY; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84871880253     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.09.021     Document Type: Article

References (35)

1. Buckley R.H. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: long-term outcomes. Immunol Res 2011, 49:25-43.
2. Hassan A., Booth C., Brightwell A., et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood 2012; Jul 12, 120:3615-3624.
3. Fernandes J.F., Rocha V., Labopin M., et al. Eurocord and Inborn Errors Working Party of European Group for Blood and Marrow Transplantation. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood?. Blood 2012, 119:2949-2955.
4. Walters M.C., Sullivan K.M. Stem-cell transplantation for sickle cell disease. N Engl J Med 2010, 362:955-956.
5. Hsieh M.M., Kang E.M., Fitzhugh C.D., et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009, 361:2309-2317.
6. Bordignon C., Notarangelo L.D., Nobili N., et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995, 270:470-475.
7. Hoogerbrugge P.M., van Beusechem V.W., Fischer A., et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 1996, 3:179-183.
8. Kohn D.B., Weinberg K.I., Nolta J.A., et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995, 1:1017-1023.
9. Aiuti A., Slavin S., Aker M., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002, 296:2410-2413.
10. Aiuti A., Cattaneo F., Galimberti S., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009, 360:447-458.
11. Gaspar H.B., Cooray S., Gilmour K.C., et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011, 3:97ra80.
12. Candotti F., Shaw K.L., Muul L., et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 2012, 120:3635-3646.
13. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288:669-672.
14. Hacein-Bey-Abina S., Hauer J., Lim A., et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010, 363:355-364.
15. Gaspar H.B., Cooray S., Gilmour K.C., et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011, 3:97ra79.
16. Hacein-Bey-Abina S., Garrigue A., Wang G.P., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142.
17. Stein S., Ott M.G., Schultze-Strasser S., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010, 16:198-204.
18. Boztug K., Schmidt M., Schwarzer A., et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010, 363:1918-1927.
19. Paruzynski A., Arens A., Gabriel R., et al. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc 2010, 5:1379-1395.
20. Brady T., Roth S.L., Malani N., et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res 2011, 39:e72.
21. Wu X., Li Y., Crise B., et al. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300:1749-1751.
22. Modlich U., Bohne J., Schmidt M., et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006, 108:2545-2553.
23. Montini E., Cesana D., Schmidt M., et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009, 119:964-975.
24. Moiani A., Paleari Y., Sartori D., et al. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 2012, 122:1653-1666.
25. Baum C., Modlich U., Göhring G., et al. Concise review: managing genotoxicity in the therapeutic modification of stem cells. Stem Cells 2011, 29:1479-1484.
26. Novak U., Harris E.A., Forrester W., et al. High-level β-globin expression after retroviral transfer of locus activation region-containing human β-globin gene derivatives into murine erythroleukemia cells. Proc Natl Acad Sci USA 1990, 87:3386-3390.
27. May C., Rivella S., Callegari J., et al. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature 2000, 406:82-86.
28. Cavazzana-Calvo M., Payen E., Negre O., et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010, 467:318-322.
29. + cells after lentiviral vector-mediated gene transfer. Blood 2011, 117:2817-2826.
30. Levasseur D.N., Ryan T.M., Pawlik K.M., et al. Correction of a mouse model of sickle cell disease: lentiviral/antisickling β-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 2003, 102:4312-4319.
31. Urbinati F., Arumugam P., Higashimoto T., et al. Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3' LTR. Mol Ther 2009, 17:1527-1536.
32. Sadelain M., Rivière I., Wang X., et al. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in β-thalassemia. Ann NY Acad Sci 2010, 1202:52-58.
33. Mansilla-Soto J., Rivière I., Sadelain M. Genetic strategies for the treatment of sickle cell anaemia. Br J Haematol 2011, 154:715-727.
34. Holt N., Wang J., Kim K., et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010, 28:839-847.
35. Brown M.P., Topham D.J., Sangster M.Y., et al. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med 1998, 4:1253-1260.